David M Briscoe

List of Publications by Citations

Source: https://exaly.com/author-pdf/9161417/david-m-briscoe-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

2,290
citations

47
ext. papers

2,485
ext. citations

24
h-index

7.8
avg, IF

4.36
L-index

#	Paper	IF	Citations
45	Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. <i>Cancer Cell</i> , 2006 , 10, 159-70	24.3	351
44	Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. <i>Circulation</i> , 2001 , 104, 2558-64	16.7	177
43	Proinflammatory functions of vascular endothelial growth factor in alloimmunity. <i>Journal of Clinical Investigation</i> , 2003 , 112, 1655-65	15.9	167
42	Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. <i>Blood</i> , 2000 , 96, 3801-3808	2.2	166
41	Angiogenesis and endothelial cell repair in renal disease and allograft rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 932-42	12.7	122
40	The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. <i>Journal of Biological Chemistry</i> , 2007 , 282, 23679-86	5.4	113
39	Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. <i>Journal of Experimental Medicine</i> , 1999 , 190, 555-66	16.6	96
38	Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 334, 193-198	3.4	81
37	Microfluidic platform for the quantitative analysis of leukocyte migration signatures. <i>Nature Communications</i> , 2014 , 5, 4787	17.4	80
36	Interactions between T lymphocytes and endothelial cells in allograft rejection. <i>Current Opinion in Immunology</i> , 1998 , 10, 525-31	7.8	79
35	The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. <i>Pediatric Transplantation</i> , 2000 , 4, 252-60	1.8	79
34	Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. <i>Journal of Immunology</i> , 2006 , 176, 3098-107	5.3	61
33	Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. <i>Journal of Immunology</i> , 2010 , 184, 545-9	5.3	60
32	Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. <i>Transplantation</i> , 2003 , 76, 224-30	1.8	55
31	Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3. European Journal of Immunology, 2011 , 41, 2291-302	6.1	51
30	Outcome of renal transplantation in children less than two years of age. <i>Kidney International</i> , 1992 , 42, 657-62	9.9	44
29	DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. <i>Physiological Reviews</i> , 2018 , 98, 1765-1803	47.9	42

28	VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 120-8	5.8	42
27	Angiogenesis in the huPBL-SCID model of human transplant rejection. <i>Transplantation</i> , 1999 , 67, 1626-3	8 1 .8	38
26	CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. <i>Journal of Immunology</i> , 2008 , 181, 8088-95	5.3	36
25	Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo. <i>Scientific Reports</i> , 2015 , 5, 11789	4.9	34
24	DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. <i>Blood</i> , 2013 , 122, 1833-42	2.2	33
23	Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. <i>Blood</i> , 2010 , 116, 1980-9	2.2	24
22	Every allograft needs a silver lining. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3645-8	15.9	23
21	Netrin-1 Augments Chemokinesis in CD4+ T Cells In Vitro and Elicits a Proinflammatory Response In Vivo. <i>Journal of Immunology</i> , 2016 , 197, 1389-98	5.3	20
20	Chronic allograft rejection: a fresh look. Current Opinion in Organ Transplantation, 2015, 20, 13-20	2.5	17
19	Microfluidic mazes to characterize T-cell exploration patterns following activation in vitro. <i>Integrative Biology (United Kingdom)</i> , 2015 , 7, 1423-31	3.7	16
18	Convergent and Divergent Migratory Patterns of Human Neutrophils inside Microfluidic Mazes. <i>Scientific Reports</i> , 2018 , 8, 1887	4.9	16
17	Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 434-442	5.8	14
16	Targeting the intragraft microenvironment and the development of chronic allograft rejection. <i>Human Immunology</i> , 2012 , 73, 1261-8	2.3	14
15	TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. <i>Transplantation</i> , 2004 , 78, 1218-21	1.8	13
14	Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. <i>Transplantation</i> , 2005 , 80, 717-22	1.8	12
13	Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation. <i>American Journal of Transplantation</i> , 2018 , 18, 2135-2147	8.7	10
12	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 1295-	·1/302	10
11	Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. <i>Pediatric Nephrology</i> , 2016 , 31, 41-51	3.2	9

10	Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro. <i>Transplantation Research</i> , 2012 , 1, 4		7
9	DEPTOR modulates activation responses in CD4 T cells and enhances immunoregulation following transplantation. <i>American Journal of Transplantation</i> , 2019 , 19, 77-88	8.7	6
8	Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 519, 667-673	3.4	4
7	T Cell-Specific Adaptor Protein Regulates Mitochondrial Function and CD4 T Regulatory Cell Activity In Vivo following Transplantation. <i>Journal of Immunology</i> , 2019 , 203, 2328-2338	5.3	4
6	The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance. <i>Current Opinion in Organ Transplantation</i> , 2017 , 22, 55-63	2.5	2
5	Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, 136-7		1
4	Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4 T cells. <i>American Journal of Transplantation</i> , 2021 ,	8.7	1
3	Transplantation Immunobiology 2009 , 1835-1866		1
2	Chemorepulsion as a novel therapeutic concept to inhibit pancreatic cancer metastasis. <i>FASEB Journal</i> , 2018 , 32, 677.12	0.9	
1	An Inhibitory Ligand of Neuropilin 2 Blocks Pancreatic Cancer Progression and Impedes Tumor Angiogenesis. <i>FASEB Journal</i> , 2019 , 33, 368.7	0.9	